Olfactory disorder in Parkinson's disease

doi:10.16352/j.issn.1001-6325.2023.06.0994

Abstract

Abstract: Olfactory dysfunction is the most common early non-motor symptom of Parkinson's disease (PD), which is used as a marker for the diagnosis of PD. The mechanism of olfactory dysfunction is very complex, which is a challenge in the research. The neuromediator such as the accumulation of α-synuclein, dopamine (DA), acetylcholine (ACh), 5-hydroxytryptamine (5-HT) and inflammatory factors are implicated in the olfactory dysfunction in PD. To further study the mechanism of olfactory dysfunction in PD may provide new ideas and therapeutic targets for treatment.

Key words: Parkinson's disease, olfactory dysfunction, α-synuclein, inflammation response, neuromediator

CLC Number:

R730.2

REN Peng, CHEN Yali, ZHANG Xianwen. Olfactory disorder in Parkinson's disease[J]. Basic & Clinical Medicine, 2023, 43(6): 994-997.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.06.0994

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I6/994

References 25

[1]	Roos DS, Klein M, Deeg DJH, et al. Prevalence of prodromal symptoms of Parkinson's disease in the late middle-aged population[J]. J Parkinsons Dis, 2022,12:967-974.
[2]	Nabizadeh F, Pirahesh K, Khalili E. Olfactory dysfunc-tion is associated with motor function only in tremor-dominant Parkinson's disease[J]. Neurol Sci, 2022,2:1-9.
[3]	Solla P, Masala C, Liscia A, et al. Sex-related differ-ences in olfactory function and evaluation of possible confounding factors among patients with Parkinson's disease[J]. J Neurol, 2020,267:57-63.
[4]	Lee YH, Bak Y, Park CH, et al. Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia[J]. Neurobiol Aging, 2020,89:63-70.
[5]	Marrero-Gonzalez P, Iranzo A, Bedoya D, et al. Prodro-mal Parkinson disease in patients with idiopathic hyposmia[J]. J Neurol, 2020,267:3673-3682.
[6]	Zhou Y, He R, Zhao Y, et al. Olfactory dysfunction and its relationship with clinical features of Parkinson's disease[J]. Front Neurol, 2020,11:1-9.
[7]	Glover A, Pillai L, Dhall R, et al. Olfactory deficits in the freezing of gait phenotype of Parkinson's disease[J]. Front Neurol, 2021,12:1-9.
[8]	Roh H, Kang J, Koh SB, et al. Hippocampal volume is related to olfactory impairment in Parkinson's disease[J]. J Neuroimaging, 2021,31:1176-1183.
[9]	Lin CY, Chang TY, Chang MH. Dysosmia Is a predictor of motor function and quality of life in patients with Parkinson's disease[J]. J Pers Med, 2022,12:1-13.
[10]	Wakabayashi K. Where and how alpha-synuclein pathology spreads in Parkinson's disease[J]. Neuropathology, 2020,40:415-425.
[11]	Uemura N, Ueda J, Yoshihara T, et al. alpha-synuclein spread from olfactory bulb causes hyposmia, anxiety, and memory loss in BAC-SNCA mice[J]. Mov Disord, 2021,36:2036-2047.
[12]	Li R, Lu Y, Zhang Q, et al. Piperine promotes autophagy flux by P2RX4 activation in SNCA/alpha-synuclein-induced Parkinson disease model[J]. Autophagy, 2022,18:559-575.
[13]	Kulkarni AS, Del Mar Cortijo M, Roberts ER, et al. Perturbation of in vivo neural activity following alpha-synuclein seeding in the olfactory bulb[J]. J Parkinsons Dis, 2020,10:1411-1427.
[14]	Pass T, Assfalg M, Tolve M, et al. The impact of mitochondrial dysfunction on dopaminergic neurons in the olfactory bulb and odor detection[J]. Mol Neurobiol, 2020,57:3646-3657.
[15]	Ma K, Han C, Zhang G, et al. Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease[J]. Biochem Biophys Res Commun, 2019,513:306-312.
[16]	Zhang W, Sun C, Shao Y, et al. Partial depletion of dopaminergic neurons in the substantia nigra impairs olfaction and alters neural activity in the olfactory bulb[J]. Sci Rep, 2019,9:254-267.
[17]	Jiang S, Berger S, Hu Y, et al. Alterations of the motor and olfactory functions related to Parkinson's disease in transgenic mice with a VMAT2-deficiency in dopaminergic neurons[J]. Front Neurosci, 2020,14:356-367.
[18]	Oh E, Park J, Youn J, et al. Olfactory dysfunction in early Parkinson's disease is associated with short latency afferent inhibition reflecting central cholinergic dysfunction[J]. Clin Neurophysiol, 2017,128:1061-1068.
[19]	Yang J, Lv DJ, Li LX, et al. Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease[J]. Neurotoxicology, 2019,73:175-182.
[20]	Fullard ME, Morley JF, Duda JE. Olfactory dysfunction as an early biomarker in Parkinson's disease[J]. Neurosci Bull, 2017,33:515-525.
[21]	Morais LH, Hara DB, Bicca MA, et al. Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson's disease[J]. Behav Pharmacol, 2018,29:199-210.
[22]	Cui C, Hong H, Shi Y, et al. Vancomycin pretreatment on MPTP-Induced Parkinson's disease mice exerts neuroprotection by suppressing inflammation both in brain and gut[J]. J Neuroimmune Pharmacol, 2022,1:1-18.
[23]	Niu H, Wang Q, Zhao W, et al. IL-1beta/IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-synuclein pathology in the olfactory bulb, substantia nigra and striatum[J]. Brain Pathol, 2020,30:1102-1118.
[24]	Zhang X, Huang W, Shao Q, et al. Drp1, a potential therapeutic target for Parkinson's disease, is involved in olfactory bulb pathological alteration in the Rotenone-induced rat model[J]. Toxicol Lett, 2020,325:1-13.
[25]	Chen Y, Zhang QS, Shao QH, et al. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP[J]. Acta Pharmacol Sin, 2019,40:991-998.